2型糖尿病患者高血压与糖尿病性神经病变的关系

目的 探讨2型糖尿病患者高血压与糖尿病性神经病变的关系。方法 利用心自主神经功能检测系统和神经电生理检测仪对107例（高血压组52例,非高血压组55例）2型糖尿病患者的心自主神经功能和肢体的末梢神经传导速度、皮肤痛温觉、振动沉进行测定,以判断心自主神经病变和末梢神经病变。结果 两组间末梢神经功能和心自主神经功能各指标除心的是距频谱分析的高频值外差异均无显著性（P＜0.05）。Logistic回归分析显示高血压与心自主神经病变显著相关（P＜0.01）,而与末梢神经病变无显著相关。结论 2型糖尿病患者高血压是心自主神经病变发病的危险因素,而与末梢神经病变无明显关系。     

Relationship between peripheral diabetic neuropathy and microvascular reactivity in patients with type 1 and type 2 diabetes mellitus -- neuropathy and microcirculation in diabetes.

The aim of the study was to evaluate differences in the relationship between peripheral diabetic neuropathy and microvascular reactivity in type 1 and type 2 diabetic patients. Twenty-eight type 1 and 37 type 2 diabetic patients were included in the study. Control groups consisted of 18 and 25, age and body mass index matched healthy persons. The presence of peripheral neuropathy was estimated by vibration perception threshold higher than 20 V evaluated by biothesiometry. Microvascular reactivity was examined by laser doppler fluxmetry using postocclusive reactive hyperemia and thermal hyperemia. The following variables of vascular reactivity were examined: peak flow after occlusion as a difference between maximal and basal perfusion (PORH (max)), mean velocity increase during postocclusive hyperemia (PORH (max)/t (1)), peak flow during thermal hyperemia (TH (max)) and the mean velocity increase in the perfusion during thermal hyperemia (TH (max)/t (2)). These parameters are expressed in perfusion units (PU) or in perfusion units per second (PU . s (-1)). The microvascular reactivity in type 1 diabetic patients without evidence of peripheral neuropathy was comparable with that in healthy persons and it was significantly higher than in type 1 diabetic patients with peripheral neuropathy in all tested parameters (PORH (max): 64 [40; 81] PU vs. 24 [17; 40] PU, p < 0.001, PORH (max)/t (1): 5.41 [2.69; 8.18] PU/s vs. 1.21 [0.69; 2.5] PU/s, p < 0.001, TH (max): 105 [77; 156] PU vs. 56 [46; 85] PU, p < 0.001 and TH (max)/t (2): 2.48 [1.67; 3.33] PU/s vs. 0.87 [0.73; 1.06] PU/s, p < 0.001). On the contrary, no difference in the microvascular reactivity parameters was found between type 2 diabetic patients with and without neuropathy (PORH (max): 48 [30; 60] PU vs. 49 [36; 57] PU, NS, PORH (max)/t (1): 3.46 [2.15; 5.19] PU/s vs. 3.29 [2.45; 4.8] PU/s, NS, TH (max): 95 [78; 156] PU vs. 97 [73; 127] PU, NS and TH (max)/t (2): 1.45 [0.95; 2.84] PU/s vs. 1.37 [1.12; 1.95] PU/s, NS). In both these groups microvascular reactivity was comparable with that estimated in the age and BMI matched healthy persons. An inverse relationship was observed between microvascular reactivity and vibratory perception threshold in type 1 diabetic patients, but it was not true in type 2 diabetic patients. We suppose that the pathogenesis of neuropathy and impaired microvascular reactivity may be differently influenced by metabolic factors in type 1 and type 2 diabetic patients.     

Diabetic peripheral neuropathy in type 2 diabetes mellitus in Korea

Diabetic peripheral neuropathy (DPN), a common and troublesome complication in patients with type 2 diabetes mellitus (T2DM), contributes to a higher risk of diabetic foot ulcer and lower limb amputation. These situations can negatively impact the quality of life of affected individuals. Despite its high prevalence and clinical importance, most diabetes mellitus patients not only do not recognize the presence of diabetic neuropathy, but also do not report their symptoms to physicians or other health care providers. Therefore, DPN is usually under diagnosed and undertreated. For early detection and appropriate intervention for DPN, a careful history, physical with neurologic examination, and prompt treatment are needed in T2DM patients.     

Diagnosis of diabetic autonomic neuropathy in young patients with diabetes mellitus type 1

Autonomic neuropathy, particularly cardiovascular autonomic neuropathy (CAN) is one of the complications of the diabetes mellitus both types. It leads to life comfort's declination but may also be the direct cause of death in diabetes mellitus patients. It seems that degree of metabolic control and duration of the disease is connected with prevalence and severity of CAN. The aim of our study was to assess cardiac autonomic function in young subjects suffered from insulin-dependent diabetes mellitus (IDDM) with relatively short duration time of the disease. We subdivided 25 (m-12, f-13) IDDM patients aged from 18 to 30 years: mean--26 +/- 38 years, with duration time of the disease up to 10 years, normotensive and without nephropathy and retinopathy. We created 25 healthy volunteers control group with similar age and sex. In all selected subjects full Ewing's battery tests were performed as well as the spectral analysis of power heart rate variability (HRV) was assessed with Finapress device (Ohmeda 2300) and automatically computed with special software. HRV in total spectrum power TP from 0.001-0.5 Hz, high frequency (HF) band from 0.15-0.3 Hz, low frequency (LF) band from 0.03-0.15 Hz and LF/HF ratio were examined both in supine and tilt. All assessed spectral values were significantly lower in IDDM patients then these in controls whereas LF/HF were respectively higher. Valsalva tests and deep breathing HR response tests were significantly differed among groups but within normal limits. We concluded that when spectral analyse was performed, in young IDDM patients with short duration time of the disease, impairment of cardiac autonomic function was observed.     

Chronic inflammatory demyelinating polyneuropathy mimicking diabetic neuropathy in a young female with type 2 diabetes mellitus

The presentations of chronic inflammatory demyelinating polyneuropathy (CIDP) overlap with those of diabetic peripheral neuropathy (DPN). We described a young girl with CIDP underlying type 2 diabetes mellitus, presenting with progressive numbness and limb weakness, who was initially misdiagnosed to have DPN. Finally immunosuppressive therapy got good response.     

2型糖尿病患者糖化血红蛋白指数与糖尿病心脏自主神经病变的相关性研究

目的:探讨2型糖尿病患者糖化血红蛋白指数（HGI）与糖尿病心脏自主神经病变（DCAN）的相关性及HGI在DCAN发病风险预测中的作用。方法:本研究为回顾性研究。选取2017年10月至2020 年5月在重庆医科大学附属第一医院内分泌科住院的993例2型糖尿病患者作为研究对象。收集所有患者的性别、年龄、糖尿病家族史、糖尿病...     

Pharmaceutical therapy of diabetes mellitus type 2

The sequelae and complications associated with type 2 diabetes mellitus can be reduced or inhibited by optimal therapy. Currently, a variety of medications are available for differentiated therapy, which should be used according to the German Diabetes Association Guidelines. Changes in lifestyle represent the basic therapeutic principle, and it is mandatory to continuously maintain these measures throughout life. If this is not adequately effective (HBA(1c) <6.5%), treatment with oral antidiabetic drugs (OAD) is necessary. Over time OAD monotherapy frequently fails, so that a combination of several oral antidiabetics is needed. The choice of oral antidiabetics is particularly dependent on the patient's body mass index and associated diseases. If combination therapy with OAD is not successful in achieving HbA1c values <6.5%, insulin therapy is required either in combination with OADs as a bedtime regimen or as intensive insulin therapy using both basal and short-term acting insulins.     

2型糖尿病的医学营养治疗

介绍2型糖尿病医学营养治疗的近年进展,认为主要应适当减少食物热卡及限制饱和脂肪酸＜7%,以控制血糖并降低心血管疾病危险等.     

Oral combination therapy for type 2 diabetes

For patients with type 2 diabetes, oral monotherapy may be initially effective for controlling blood glucose, but it is associated with a high secondary failure rate. (Primary failure is frequent only in patients with high baseline blood glucose at the time of beginning monotherapy, whereas secondary failure is to be expected in the course of the disease.) The different classes of oral agents used to treat type 2 diabetes have complementary mechanisms of action, and their use in combination often results in blood glucose reductions that are significantly greater than those that can be obtained with maximal doses of any single drug. A wide range of combinations (e.g. sulfonylurea plus metformin, a thiazolidinedione, or acarbose; metformin plus a thiazolidinedione or acarbose) have been used effectively to achieve glycemic control in patients in whom oral monotherapy has failed. The high secondary failure rates for oral monotherapy - and, moreover, the high primary failure rate in patients with very high blood glucose at diagnosis - coupled with the effectiveness of combination treatment, support the suggestion that multiple-drug regimens be considered for initial pharmacologic treatment in patients with symptomatic type 2 diabetes whose blood glucose is not controlled by diet alone.     

The effect of autonomous neuropathy on bowel preparation in type 2 diabetes mellitus

Introduction  

The need for colonoscopy is common among diabetics. In this study, we aimed to evaluate the effect of autonomous neuropathy on bowel preparation in type 2 diabetes mellitus (DM) patients.     

Association of reduced glyoxalase 1 activity and painful peripheral diabetic neuropathy in type 1 and 2 diabetes mellitus patients

AimsThe present study was undertaken to investigate the relationship between glyoxalase 1 (Glo1) enzyme activity and painful diabetic neuropathy (DN) in patients with diabetes mellitus.MethodsGlo1 activity and biochemical markers were determined in blood samples from 108 patients with type 1 diabetes, 109 patients with type 2 diabetes, and 132 individuals without diabetes as a control. Painful and painless peripheral DN was assessed and multivariate regression analysis was used to determine independent association of Glo1 activity with occurrence of painful DN.ResultsIn patients with type 1 and type 2 diabetes mellitus and painful DN compared to patients with painless DN, Glo1 activity was significantly reduced by 12 and 14%, respectively. The increase in Glo1 activity was significantly associated with reduced occurrence of painful DN after adjusting for confounders by multivariate analysis.ConclusionsOur results demonstrate for the first time that Glo1 activity is lower in patients with both types of diabetes mellitus who were diagnosed with painful DN. These data support the hypothesis that Glo1 activity modulates the phenotype of DN and warrant further investigation into the role of Glo1 in DN.     

自然疗法治疗2型糖尿病的研究进展

虽然传统的降糖药物和胰岛素在控制2型糖尿病方面有较明确的疗效,然而,终身接受药物治疗对患者的身心健康危害极大.近年来,物理疗法、情志疗法、运动疗法、食物疗法等自然疗法在2型糖尿病中的应用越来越受到重视,且疗效显著.物理疗法是应用一种或多种物理因素作用于人体,以防治疾病的方法;情志疗法是通过社会、家庭和患者的积极沟通,使患者保持积极乐观的心态和稳定的情绪,树立战胜疾病的信心,有助于疾病的康复;运动疗法是指有治疗意义的运动,通过有计划的、多样性的、合理的重复性运动达到一定的促进健康的目的;饮食疗法即利用食物来影响机体各方面的功能,使其获得健康或疾病防治的一种方法.